Novel E2 glycoprotein tetramer detects hepatitis C virus-specific memory B cells

Journal of Immunology

Volumn 197, Issue 12, 2016, Pages 4848-4858

  Boisvert, Maude ^a   Zhang, Wanrui ^b   Elrod, Elizabeth J ^b   Bernard, Nicole F ^c,d   Villeneuve, Jean Pierre ^a,e   Bruneau, Julie ^a,e   Marcotrigiano, Joseph ^f   Shoukry, Naglaa H ^a,e   Grakoui, Arash ^b,g  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b EMORY UNIVERSITY   (United States)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f RUTGERS UNIVERSITY   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E2; TETRAMER; GLYCOPROTEIN E2, HEPATITIS C VIRUS; PROTEIN BINDING; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELL EXPANSION; CELL MATURATION; CELL SELECTION; CELL SPECIFICITY; CLONAL VARIATION; CONTROLLED STUDY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MEMORY CELL; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS IDENTIFICATION; VIRUS STRAIN; ADULT; B LYMPHOCYTE; CROSS-SECTIONAL STUDY; FEMALE; GENETICS; HEK293 CELL LINE; HEPACIVIRUS; HEPATITIS C; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; MALE; METABOLISM; PROCEDURES; PROTEIN ENGINEERING; VIROLOGY;

ADULT; B-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; FEMALE; HEK293 CELLS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; IMMUNOLOGIC TESTS; MALE; PROTEIN BINDING; PROTEIN ENGINEERING; VIRAL ENVELOPE PROTEINS;

EID: 85002488017     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600763     Document Type: Article

References (51)

1. Suryaprasad, A. G., J. Z. White, F. Xu, B. A. Eichler, J. Hamilton, A. Patel, S. B. Hamdounia, D. R. Church, K. Barton, C. Fisher, et al. 2014. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin. Infect. Dis. 59: 1411-1419.
2. Schinazi, R., P. Halfon, P. Marcellin, and T. Asselah. 2014. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 34(Suppl 1): 69-78.
3. Simmons, B., J. Saleem, A. Hill, R. D. Riley, and G. S. Cooke. 2016. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin. Infect. Dis. 62: 683-694.
4. Swadling, L., S. Capone, R. D. Antrobus, A. Brown, R. Richardson, E. W. Newell, J. Halliday, C. Kelly, D. Bowen, J. Fergusson, et al. 2014. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 6: 261ra153.
5. Cashman, S. B., B. D. Marsden, and L. B. Dustin. 2014. The humoral immune response to HCV: understanding is key to vaccine development. Front. Immunol. 5:550.
6. Law, J. L., C. Chen, J. Wong, D. Hockman, D. M. Santer, S. E. Frey, R. B. Belshe, T. Wakita, J. Bukh, C. T. Jones, et al. 2013. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One 8: e59776.
7. Logvinoff, C., M. E. Major, D. Oldach, S. Heyward, A. Talal, P. Balfe, S. M. Feinstone, H. Alter, C. M. Rice, and J. A. McKeating. 2004. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 101: 10149-10154.
8. Netski, D. M., T. Mosbruger, E. Depla, G. Maertens, S. C. Ray, R. G. Hamilton, S. Roundtree, D. L. Thomas, J. McKeating, and A. Cox. 2005. Humoral immune response in acute hepatitis C virus infection. Clin. Infect. Dis. 41: 667-675.
9. Farci, P., A. Shimoda, D. Wong, T. Cabezon, D. De Gioannis, A. Strazzera, Y. Shimizu, M. Shapiro, H. J. Alter, and R. H. Purcell. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. USA 93: 15394-15399.
10. Morin, T. J., T. J. Broering, B. A. Leav, B. M. Blair, K. J. Rowley, E. N. Boucher, Y. Wang, P. S. Cheslock, M. Knauber, D. B. Olsen, et al. 2012. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog. 8: e1002895.
11. Law, M., T. Maruyama, J. Lewis, E. Giang, A. W. Tarr, Z. Stamataki, P. Gastaminza, F. V. Chisari, I. M. Jones, R. I. Fox, et al. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14: 25-27.
12. Vanwolleghem, T., J. Bukh, P. Meuleman, I. Desombere, J. C. Meunier, H. Alter, R. H. Purcell, and G. Leroux-Roels. 2008. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 47: 1846-1855.
13. Dowd, K. A., D. M. Netski, X. H. Wang, A. L. Cox, and S. C. Ray. 2009. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 136: 2377-2386.
14. Osburn, W. O., A. E. Snider, B. L. Wells, R. Latanich, J. R. Bailey, D. L. Thomas, A. L. Cox, and S. C. Ray. 2014. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 59: 2140-2151.
15. Pestka, J. M., M. B. Zeisel, E. Bläser, P. Schürmann, B. Bartosch, F. L. Cosset, A. H. Patel, H. Meisel, J. Baumert, S. Viazov, et al. 2007. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA 104: 6025-6030.
16. Raghuraman, S., H. Park, W. O. Osburn, E. Winkelstein, B. R. Edlin, and B. Rehermann. 2012. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J. Infect. Dis. 205: 763-771.
17. Esteban-Riesco, L., F. Depaulis, A. Moreau, Y. Bacq, F. Dubois, A. Goudeau, and C. Gaudy-Graffin. 2013. Rapid and sustained autologous neutralizing response leading to early spontaneous recovery after HCV infection. Virology 444: 90-99.
18. Osburn, W. O., B. E. Fisher, K. A. Dowd, G. Urban, L. Liu, S. C. Ray, D. L. Thomas, and A. L. Cox. 2010. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138: 315-324.
19. Thimme, R., J. Bukh, H. C. Spangenberg, S. Wieland, J. Pemberton, C. Steiger, S. Govindarajan, R. H. Purcell, and F. V. Chisari. 2002. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. USA 99: 15661-15668.
20. Post, J. J., Y. Pan, A. J. Freeman, C. E. Harvey, P. A. White, P. Palladinetti, P. S. Haber, G. Marinos, M. H. Levy, J. M. Kaldor, et al; Hepatitis C Incidence and Transmission in Prisons Study (HITS) Group. 2004. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J. Infect. Dis. 189: 1846-1855.
21. Meyer, M. F., M. Lehmann, M. Cornberg, J. Wiegand, M. P. Manns, C. Klade, and H. Wedemeyer. 2007. Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol. J. 4:58.
22. Takaki, A., M. Wiese, G. Maertens, E. Depla, U. Seifert, A. Liebetrau, J. L. Miller, M. P. Manns, and B. Rehermann. 2000. Cellular immune responses persist and humoral responses decrease two decades after recovery from a singlesource outbreak of hepatitis C. Nat. Med. 6: 578-582.
23. Sugalski, J. M., B. Rodriguez, S. Moir, and D. D. Anthony. 2010. Peripheral blood B cell subset skewing is associated with altered cell cycling and intrinsic resistance to apoptosis and reflects a state of immune activation in chronic hepatitis C virus infection. J. Immunol. 185: 3019-3027.
24. Franz, B., K. F. May, Jr., G. Dranoff, and K. Wucherpfennig. 2011. Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. Blood 118: 348-357.
25. Morris, L., X. Chen, M. Alam, G. Tomaras, R. Zhang, D. J. Marshall, B. Chen, R. Parks, A. Foulger, F. Jaeger, et al. 2011. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One 6: e23532.
26. Naldini, L., U. Blömer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
27. Grebely, J., M. D. Morris, T. M. Rice, J. Bruneau, A. L. Cox, A. Y. Kim, B. H. McGovern, N. H. Shoukry, G. Lauer, L. Maher, et al; InC Study Group. 2013. Cohort profile: the international collaboration of incident HIVand hepatitis C in injecting cohorts (InC3) study. Int. J. Epidemiol. 42: 1649-1659.
28. Badr, G., N. Bédard, M. S. Abdel-Hakeem, L. Trautmann, B. Willems, J. P. Villeneuve, E. K. Haddad, R. P. Sékaly, J. Bruneau, and N. H. Shoukry. 2008. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J. Virol. 82: 10017-10031.
29. Kared, H., T. Fabre, N. Bédard, J. Bruneau, and N. H. Shoukry. 2013. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog. 9: e1003422.
30. Khan, A. G., J. Whidby, M. T. Miller, H. Scarborough, A. V. Zatorski, A. Cygan, A. A. Price, S. A. Yost, C. D. Bohannon, J. Jacob, et al. 2014. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509: 381-384.
31. Jahnmatz, M., G. Kesa, E. Netterlid, A. M. Buisman, R. Thorstensson, and N. Ahlborg. 2013. Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses. J. Immunol. Methods 391: 50-59.
32. Yousfi Monod, M., V. Giudicelli, D. Chaume, and M. P. Lefranc. 2004. IMGT/ JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics 20(Suppl 1): i379-i385.
33. Whidby, J., G. Mateu, H. Scarborough, B. Demeler, A. Grakoui, and J. Marcotrigiano. 2009. Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. J. Virol. 83: 11078-11089.
34. Dickey, C., U. Ziegner, M. G. Agadjanyan, V. Srikantan, Y. Refaeli, A. Prabhu, A. Sato, W. V. Williams, D. B. Weiner, and K. E. Ugen. 2000. Murine monoclonal antibodies biologically active against the amino region of HIV-1 gp120: isolation and characterization. DNA Cell Biol. 19: 243-252.
35. Miqueu, P., M. Guillet, N. Degauque, J. C. Doré, J. P. Soulillou, and S. Brouard. 2007. Statistical analysis of CDR3 length distributions for the assessment of T and B cell repertoire biases. Mol. Immunol. 44: 1057-1064.
36. De Silva, N. S., and U. Klein. 2015. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15: 137-148.
37. Bassett, S. E., D. L. Thomas, K. M. Brasky, and R. E. Lanford. 1999. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J. Virol. 73: 1118-1126.
38. Lavie, M., S. Sarrazin, R. Montserret, V. Descamps, T. F. Baumert, G. Duverlie, K. Séron, F. Penin, and J. Dubuisson. 2014. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. J. Virol. 88: 10584-10597.
39. Owsianka, A. M., J. M. Timms, A.W. Tarr, R. J. Brown, T. P. Hickling, A. Szwejk, K. Bienkowska-Szewczyk, B. J. Thomson, A. H. Patel, and J. K. Ball. 2006. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J. Virol. 80: 8695-8704.
40. Kong, L., E. Giang, J. B. Robbins, R. L. Stanfield, D. R. Burton, I. A. Wilson, and M. Law. 2012. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc. Natl. Acad. Sci. USA 109: 9499-9504.
41. Keck, Z., W. Wang, Y. Wang, P. Lau, T. H. Carlsen, J. Prentoe, J. Xia, A. H. Patel, J. Bukh, and S. K. Foung. 2013. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J. Virol. 87: 37-51.
42. Hadlock, K. G., R. E. Lanford, S. Perkins, J. Rowe, Q. Yang, S. Levy, P. Pileri, S. Abrignani, and S. K. Foung. 2000. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 74: 10407-10416.
43. Mc Guire, P. J., C. Cunningham-Rundles, H. Ochs, and G. A. Diaz. 2010. Oligoclonality, impaired class switch and B-cell memory responses in WHIM syndrome. Clin. Immunol. 135: 412-421.
44. Galson, J. D., E. A. Clutterbuck, J. Trück, M. N. Ramasamy, M. Münz, A. Fowler, V. Cerundolo, A. J. Pollard, G. Lunter, and D. F. Kelly. 2015. BCR repertoire sequencing: different patterns of B-cell activation after two Meningococcal vaccines. Immunol. Cell Biol. 93: 885-895.
45. Racanelli, V., C. Brunetti, V. De Re, L. Caggiari, M. De Zorzi, P. Leone, F. Perosa, A. Vacca, and F. Dammacco. 2011. Antibody V(h) repertoire differences between resolving and chronically evolving hepatitis C virus infections. PLoS One 6: e25606.
46. Gill, K., H. Ghazinian, R. Manch, and R. Gish. 2016. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol. Int. 10: 415-423.
47. Sansonno, D., G. Lauletta, V. De Re, F. A. Tucci, P. Gatti, V. Racanelli, M. Boiocchi, and F. Dammacco. 2004. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur. J. Immunol. 34: 126-136.
48. Chan, C. H., K. G. Hadlock, S. K. Foung, and S. Levy. 2001. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97: 1023-1026.
49. Ivanovski, M., F. Silvestri, G. Pozzato, S. Anand, C. Mazzaro, O. R. Burrone, and D. G. Efremov. 1998. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 91: 2433-2442.
50. Thapa, M., R. Chinnadurai, V. M. Velazquez, D. Tedesco, E. Elrod, J. H. Han, P. Sharma, C. Ibegbu, A. Gewirtz, F. Anania, et al. 2015. Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity. Hepatology 61: 2067-2079.
51. Raziorrouh, B., K. Sacher, R. G. Tawar, F. Emmerich, C. Neumann-Haefelin, T. F. Baumert, R. Thimme, and T. Boettler. 2016. Virus-specific CD4+ T Cells have functional and phenotypic characteristics of follicular T-helper cells in patients with acute and chronic HCV infections. Gastroenterology 150(3): 696-706.e3.